Mednax to Present at 2022 J.P. Morgan Global High Yield and Leveraged Finance Conference

Rhea-AI Summary

Mednax, Inc. (NYSE: MD) will present at J.P. Morgan’s 2022 Global High Yield and Leveraged Finance Conference on February 28, 2022, at 10:00 a.m. ET in Miami. The event will be accessible through live audio webcasts. Mednax is known for providing physician services under the Pediatrix brand, specializing in pediatric and maternal-fetal care with over 4,700 affiliated clinicians across 38 states and Puerto Rico. Founded in 1979, the company emphasizes high-quality, evidence-based care, supported by a strong commitment to research and education.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Mednax, Inc. (NYSE: MD) today announced that it will present on Monday, February 28, 2022 at 10:00 a.m. ET to investors attending J.P. Morgan’s 2022 Global High Yield and Leveraged Finance Conference in Miami. The presentation will be broadcast through live audio webcasts.

ABOUT MEDNAX

Mednax, Inc. is a national medical group comprised of the nation’s leading providers of physician services practicing under the Pediatrix® brand. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by 18 pediatric subspecialties, as well as a newly expanded area of primary and urgent care clinics. The group’s high-quality, evidence-based care is bolstered by investments in research, education, quality-improvement and safety initiatives. The company was founded in 1979 as a single affiliated neonatology practice and today provides its highly focused and often critical care services through more than 4,700 affiliated physicians and other clinicians in 38 states and Puerto Rico. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn, Twitter and the Pediatrix blog. Mednax investment information can be found at www.mednax.com/investors.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the COVID-19 pandemic on the Company and its financial condition and results of operations; the effects of economic conditions on the Company’s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company’s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the impact of surprise billing legislation; the Company’s ability to comply with the terms of its debt financing arrangements; the Company’s transition to a third-party revenue cycle management provider; the impact of the divestiture of the Company’s anesthesiology and radiology medical groups; the impact of management transitions; the timing and contribution of future acquisitions; the effects of share repurchases; and the effects of the Company’s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005323/en/

Charles Lynch

Senior Vice President, Finance and Strategy

954-384-0175 ext. 5692

charles_lynch@mednax.com

Source: Mednax, Inc.

FAQ

When will Mednax present at the J.P. Morgan conference?

Mednax will present on February 28, 2022, at 10:00 a.m. ET.

Where is the J.P. Morgan Global High Yield and Leveraged Finance Conference taking place?

The conference will be held in Miami.

What is Mednax's specialty?

Mednax specializes in pediatric and maternal-fetal care, providing coordinated services across hospital and office settings.

How many clinicians are associated with Mednax?

Mednax has over 4,700 affiliated physicians and clinicians.

What brand does Mednax operate under?

Mednax operates under the Pediatrix brand.